 Halis Akturk
Concepts (198)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 1 | 50 | 2024 | 3360 | 9.030 |
Why?
| | Blood Glucose Self-Monitoring | 29 | 2024 | 534 | 5.240 |
Why?
| | Blood Glucose | 32 | 2024 | 1939 | 3.850 |
Why?
| | Hypoglycemic Agents | 20 | 2023 | 1032 | 3.470 |
Why?
| | Hypoglycemia | 7 | 2023 | 400 | 3.140 |
Why?
| | Diabetic Ketoacidosis | 7 | 2022 | 168 | 2.560 |
Why?
| | Antineoplastic Agents, Immunological | 4 | 2022 | 156 | 2.170 |
Why?
| | Insulin | 21 | 2023 | 2162 | 2.110 |
Why?
| | Programmed Cell Death 1 Receptor | 4 | 2019 | 197 | 1.890 |
Why?
| | Diabetes Mellitus, Type 2 | 11 | 2023 | 2174 | 1.700 |
Why?
| | Ketosis | 2 | 2022 | 13 | 1.650 |
Why?
| | Insulins | 3 | 2023 | 34 | 1.650 |
Why?
| | Hyperglycemia | 3 | 2021 | 312 | 1.610 |
Why?
| | Device Removal | 2 | 2021 | 127 | 1.390 |
Why?
| | Antibodies, Monoclonal | 3 | 2020 | 1284 | 1.330 |
Why?
| | Insulin Infusion Systems | 10 | 2023 | 304 | 1.110 |
Why?
| | Pancreas, Artificial | 2 | 2023 | 71 | 1.010 |
Why?
| | Humans | 69 | 2024 | 118972 | 0.990 |
Why?
| | Cannabis | 3 | 2022 | 382 | 0.980 |
Why?
| | Melanoma | 2 | 2022 | 664 | 0.970 |
Why?
| | Testosterone | 2 | 2017 | 351 | 0.920 |
Why?
| | Sweetening Agents | 1 | 2023 | 52 | 0.900 |
Why?
| | Cell Cycle Checkpoints | 2 | 2020 | 87 | 0.870 |
Why?
| | HLA-DR Antigens | 1 | 2022 | 224 | 0.820 |
Why?
| | Adult | 27 | 2024 | 31512 | 0.800 |
Why?
| | Insulin, Long-Acting | 3 | 2021 | 49 | 0.780 |
Why?
| | Blindness | 1 | 2020 | 35 | 0.740 |
Why?
| | B7-H1 Antigen | 2 | 2019 | 144 | 0.730 |
Why?
| | Diabetes Mellitus | 4 | 2022 | 942 | 0.680 |
Why?
| | Biosensing Techniques | 1 | 2020 | 107 | 0.660 |
Why?
| | Prostheses and Implants | 1 | 2020 | 141 | 0.660 |
Why?
| | Pregnancy in Diabetics | 1 | 2019 | 88 | 0.660 |
Why?
| | Thyroid Hormones | 1 | 2018 | 55 | 0.630 |
Why?
| | Sulfonylurea Compounds | 1 | 2018 | 44 | 0.630 |
Why?
| | Postprandial Period | 1 | 2018 | 96 | 0.620 |
Why?
| | Nonprescription Drugs | 1 | 2018 | 67 | 0.600 |
Why?
| | Thyroidectomy | 1 | 2017 | 54 | 0.600 |
Why?
| | Hypoparathyroidism | 1 | 2017 | 4 | 0.600 |
Why?
| | Osteomalacia | 1 | 2017 | 4 | 0.600 |
Why?
| | Wolfram Syndrome | 1 | 2017 | 4 | 0.600 |
Why?
| | Eunuchism | 1 | 2016 | 4 | 0.600 |
Why?
| | Immunologic Factors | 1 | 2019 | 225 | 0.580 |
Why?
| | Hypogonadism | 1 | 2017 | 77 | 0.570 |
Why?
| | Quality of Life | 3 | 2023 | 2366 | 0.570 |
Why?
| | Hormone Replacement Therapy | 1 | 2016 | 80 | 0.550 |
Why?
| | Graft Rejection | 1 | 2018 | 555 | 0.510 |
Why?
| | Protein Kinase Inhibitors | 1 | 2020 | 811 | 0.500 |
Why?
| | Elephantiasis | 1 | 2014 | 3 | 0.490 |
Why?
| | Adrenal Cortex Hormones | 1 | 2018 | 521 | 0.490 |
Why?
| | Dietary Supplements | 1 | 2018 | 467 | 0.480 |
Why?
| | Thyroid Neoplasms | 1 | 2017 | 278 | 0.480 |
Why?
| | Cryptogenic Organizing Pneumonia | 1 | 2013 | 17 | 0.460 |
Why?
| | Antibodies, Antineutrophil Cytoplasmic | 1 | 2013 | 35 | 0.450 |
Why?
| | Alcohol Drinking | 1 | 2017 | 652 | 0.410 |
Why?
| | Male | 21 | 2024 | 57801 | 0.410 |
Why?
| | Middle Aged | 11 | 2023 | 27617 | 0.360 |
Why?
| | Female | 18 | 2024 | 61564 | 0.340 |
Why?
| | Young Adult | 9 | 2023 | 10793 | 0.340 |
Why?
| | Cardiovascular Diseases | 2 | 2017 | 1798 | 0.330 |
Why?
| | Neoplasms | 2 | 2020 | 2179 | 0.320 |
Why?
| | Self-Injurious Behavior | 2 | 2020 | 120 | 0.320 |
Why?
| | Technology | 3 | 2023 | 83 | 0.300 |
Why?
| | Treatment Outcome | 6 | 2022 | 9342 | 0.290 |
Why?
| | Immunotherapy | 2 | 2020 | 493 | 0.260 |
Why?
| | Weight Gain | 2 | 2018 | 493 | 0.260 |
Why?
| | Suicide | 2 | 2020 | 500 | 0.230 |
Why?
| | Sensitivity and Specificity | 2 | 2022 | 1795 | 0.230 |
Why?
| | Receptors, Glucagon | 1 | 2022 | 23 | 0.220 |
Why?
| | Diagnosis, Differential | 3 | 2017 | 1384 | 0.220 |
Why?
| | Diabetic Retinopathy | 1 | 2024 | 160 | 0.210 |
Why?
| | Ketone Bodies | 1 | 2021 | 17 | 0.210 |
Why?
| | 3-Hydroxybutyric Acid | 1 | 2021 | 15 | 0.210 |
Why?
| | Retrospective Studies | 5 | 2024 | 12978 | 0.210 |
Why?
| | Gastric Emptying | 1 | 2021 | 40 | 0.200 |
Why?
| | Breath Tests | 1 | 2021 | 89 | 0.200 |
Why?
| | Ketones | 1 | 2021 | 45 | 0.200 |
Why?
| | Reference Standards | 1 | 2021 | 176 | 0.200 |
Why?
| | Infrared Rays | 1 | 2021 | 23 | 0.200 |
Why?
| | Adolescent | 7 | 2023 | 18480 | 0.200 |
Why?
| | Energy Intake | 1 | 2023 | 447 | 0.190 |
Why?
| | Risk Factors | 6 | 2019 | 9000 | 0.190 |
Why?
| | Health Behavior | 2 | 2023 | 720 | 0.180 |
Why?
| | Alleles | 1 | 2022 | 832 | 0.180 |
Why?
| | Gastroparesis | 1 | 2019 | 10 | 0.180 |
Why?
| | Child | 5 | 2023 | 19129 | 0.170 |
Why?
| | Insulin Aspart | 1 | 2018 | 26 | 0.160 |
Why?
| | Prevalence | 3 | 2023 | 2326 | 0.160 |
Why?
| | Glucosides | 1 | 2018 | 39 | 0.160 |
Why?
| | Glycosides | 1 | 2018 | 34 | 0.160 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2022 | 667 | 0.160 |
Why?
| | Benzhydryl Compounds | 1 | 2018 | 60 | 0.160 |
Why?
| | Injections | 1 | 2018 | 167 | 0.160 |
Why?
| | Cost of Illness | 1 | 2019 | 258 | 0.150 |
Why?
| | United States Food and Drug Administration | 1 | 2018 | 175 | 0.150 |
Why?
| | Antidiuretic Agents | 1 | 2017 | 7 | 0.150 |
Why?
| | Ergolines | 1 | 2016 | 3 | 0.150 |
Why?
| | Software | 1 | 2021 | 613 | 0.150 |
Why?
| | Marijuana Abuse | 1 | 2019 | 209 | 0.150 |
Why?
| | Self Care | 1 | 2019 | 357 | 0.150 |
Why?
| | Dopamine Agonists | 1 | 2016 | 30 | 0.150 |
Why?
| | Positron Emission Tomography Computed Tomography | 1 | 2017 | 71 | 0.150 |
Why?
| | Administration, Inhalation | 1 | 2018 | 656 | 0.140 |
Why?
| | Hydrocortisone | 1 | 2018 | 273 | 0.140 |
Why?
| | Prolactin | 1 | 2016 | 96 | 0.140 |
Why?
| | Osteosarcoma | 1 | 2017 | 71 | 0.140 |
Why?
| | Patient Admission | 1 | 2018 | 176 | 0.140 |
Why?
| | Health Personnel | 1 | 2022 | 588 | 0.140 |
Why?
| | Marijuana Smoking | 1 | 2019 | 220 | 0.140 |
Why?
| | Cross-Sectional Studies | 2 | 2023 | 4552 | 0.140 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2021 | 1244 | 0.140 |
Why?
| | Drug Delivery Systems | 1 | 2018 | 306 | 0.130 |
Why?
| | Pituitary Neoplasms | 1 | 2016 | 165 | 0.130 |
Why?
| | Case-Control Studies | 1 | 2022 | 3171 | 0.130 |
Why?
| | Bone Neoplasms | 1 | 2017 | 199 | 0.130 |
Why?
| | Peptostreptococcus | 1 | 2014 | 2 | 0.130 |
Why?
| | Lymphedema | 1 | 2014 | 21 | 0.120 |
Why?
| | Endocarditis, Bacterial | 1 | 2014 | 37 | 0.120 |
Why?
| | United States | 3 | 2023 | 12555 | 0.120 |
Why?
| | Mitral Valve Insufficiency | 1 | 2014 | 62 | 0.120 |
Why?
| | Prognosis | 2 | 2020 | 3443 | 0.120 |
Why?
| | Pilot Projects | 1 | 2018 | 1419 | 0.120 |
Why?
| | Heart Diseases | 1 | 2017 | 341 | 0.120 |
Why?
| | Age Factors | 2 | 2019 | 2995 | 0.120 |
Why?
| | Gram-Positive Bacterial Infections | 1 | 2014 | 67 | 0.120 |
Why?
| | Prospective Studies | 2 | 2021 | 6471 | 0.110 |
Why?
| | TRPC Cation Channels | 1 | 2012 | 11 | 0.110 |
Why?
| | Sex Characteristics | 1 | 2017 | 671 | 0.110 |
Why?
| | Incidence | 1 | 2019 | 2424 | 0.110 |
Why?
| | Platelet-Derived Growth Factor | 1 | 2012 | 83 | 0.110 |
Why?
| | Autoimmunity | 1 | 2018 | 831 | 0.110 |
Why?
| | Lymphokines | 1 | 2012 | 122 | 0.110 |
Why?
| | Hemodynamics | 1 | 2017 | 1003 | 0.110 |
Why?
| | Cough | 1 | 2013 | 102 | 0.110 |
Why?
| | Kidney Transplantation | 1 | 2018 | 585 | 0.110 |
Why?
| | Radiography, Thoracic | 1 | 2013 | 164 | 0.100 |
Why?
| | Risk Assessment | 2 | 2019 | 3057 | 0.100 |
Why?
| | Neuroprotective Agents | 1 | 2012 | 111 | 0.100 |
Why?
| | Pregnancy | 2 | 2022 | 5690 | 0.100 |
Why?
| | Skin Neoplasms | 1 | 2018 | 762 | 0.100 |
Why?
| | Biomarkers, Tumor | 1 | 2017 | 1059 | 0.100 |
Why?
| | Acute Coronary Syndrome | 1 | 2014 | 257 | 0.100 |
Why?
| | Body Mass Index | 1 | 2017 | 2092 | 0.090 |
Why?
| | Blood Pressure | 1 | 2016 | 1664 | 0.090 |
Why?
| | Hospitalization | 1 | 2018 | 1785 | 0.090 |
Why?
| | Biopsy | 1 | 2013 | 1079 | 0.090 |
Why?
| | Colorado | 1 | 2019 | 4196 | 0.080 |
Why?
| | Weight Loss | 1 | 2013 | 655 | 0.080 |
Why?
| | Chronic Disease | 1 | 2014 | 1636 | 0.080 |
Why?
| | Postoperative Complications | 1 | 2018 | 2235 | 0.080 |
Why?
| | Hypertension | 1 | 2016 | 1203 | 0.080 |
Why?
| | Surveys and Questionnaires | 1 | 2019 | 4708 | 0.070 |
Why?
| | Hypoxia | 1 | 2013 | 963 | 0.070 |
Why?
| | Reproducibility of Results | 2 | 2022 | 2874 | 0.060 |
Why?
| | Apoptosis | 1 | 2012 | 2484 | 0.060 |
Why?
| | Transaminases | 1 | 2022 | 26 | 0.060 |
Why?
| | Multicenter Studies as Topic | 1 | 2023 | 253 | 0.050 |
Why?
| | Glucagon | 1 | 2022 | 97 | 0.050 |
Why?
| | Lipoproteins, LDL | 1 | 2022 | 138 | 0.050 |
Why?
| | Needles | 1 | 2022 | 56 | 0.050 |
Why?
| | Benchmarking | 1 | 2022 | 172 | 0.050 |
Why?
| | Fear | 1 | 2023 | 307 | 0.050 |
Why?
| | Animals | 3 | 2018 | 33381 | 0.050 |
Why?
| | Double-Blind Method | 1 | 2022 | 1687 | 0.040 |
Why?
| | Skin | 1 | 2022 | 657 | 0.040 |
Why?
| | Longitudinal Studies | 1 | 2024 | 2513 | 0.040 |
Why?
| | Glucose | 1 | 2022 | 953 | 0.040 |
Why?
| | Quality Improvement | 1 | 2023 | 963 | 0.030 |
Why?
| | Adaptation, Psychological | 1 | 2019 | 557 | 0.030 |
Why?
| | Mass Spectrometry | 1 | 2018 | 681 | 0.030 |
Why?
| | Global Health | 1 | 2017 | 310 | 0.030 |
Why?
| | Ceftriaxone | 1 | 2014 | 17 | 0.030 |
Why?
| | Echocardiography, Transesophageal | 1 | 2014 | 89 | 0.030 |
Why?
| | Vancomycin | 1 | 2014 | 79 | 0.030 |
Why?
| | ATPases Associated with Diverse Cellular Activities | 1 | 2012 | 5 | 0.030 |
Why?
| | Receptor, IGF Type 1 | 1 | 2013 | 59 | 0.030 |
Why?
| | Follow-Up Studies | 1 | 2022 | 4596 | 0.030 |
Why?
| | Phosphatidylinositol 3-Kinase | 1 | 2012 | 27 | 0.030 |
Why?
| | Glycogen Synthase Kinase 3 beta | 1 | 2012 | 65 | 0.030 |
Why?
| | Insulin Glargine | 1 | 2013 | 72 | 0.030 |
Why?
| | Tomography, X-Ray Computed | 1 | 2022 | 2436 | 0.030 |
Why?
| | Glycogen Synthase Kinase 3 | 1 | 2012 | 83 | 0.030 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2012 | 139 | 0.030 |
Why?
| | Neuroblastoma | 1 | 2012 | 135 | 0.030 |
Why?
| | Registries | 1 | 2019 | 1810 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2014 | 965 | 0.020 |
Why?
| | Microtubule-Associated Proteins | 1 | 2012 | 188 | 0.020 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2019 | 1185 | 0.020 |
Why?
| | Aged | 2 | 2021 | 19657 | 0.020 |
Why?
| | Dementia | 1 | 2012 | 208 | 0.020 |
Why?
| | Phosphorylation | 1 | 2012 | 1633 | 0.020 |
Why?
| | Myocardial Infarction | 1 | 2014 | 968 | 0.020 |
Why?
| | Calcium | 1 | 2012 | 1169 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2012 | 2851 | 0.020 |
Why?
| | Anti-Bacterial Agents | 1 | 2014 | 1510 | 0.020 |
Why?
| | Neurons | 1 | 2012 | 1345 | 0.020 |
Why?
| | Rats | 1 | 2012 | 5392 | 0.010 |
Why?
| | Signal Transduction | 1 | 2012 | 4709 | 0.010 |
Why?
| | HIV Infections | 1 | 2012 | 2459 | 0.010 |
Why?
|
|
Akturk's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|